Back to search results

Childhood Cancer Predisposition Study (CCPS)

The Childhood Cancer Predisposition Study (CCPS) is an observational study looking to understand more about children who have a higher chance of developing cancer due to certain genetic conditions (cancer predisposition syndromes or CPS). This study will collect information and samples from children with CPS and their family members over up to 10 years. The goal is to learn how these conditions progress, improve ways to watch for cancer, and find better ways to prevent it. You might be able to join if you are under 21 and have a diagnosed CPS, whether or not you've had cancer. The study is currently unclear about its recruitment status.

Study design
This is an observational study planning to enroll 1050 participants, including children with cancer predisposition syndromes and their relatives.
What's involved
Participants will have demographic and diagnostic data collected at enrollment, followed by at least annual check-ins for up to 10 years.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 10 years to define the natural history of the disease and evaluate surveillance strategies.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04511806

Childhood Cancer Predisposition Study (CCPS)

Recruiting
Not specifiedAll AgesObservational
Emory University
~1,050 participants
Updated 2025-10-29 on ClinicalTrials.gov
What's tested:Registry

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Establish and maintain a framework for recruitment, participation, and surveillance of children with cancer predisposition syndromes (CPS) in clinical and translational research studies.
Measured over Up to 10 years
+2 more outcomes measured

Conditions

Pediatric Cancer

Explore related trials

Childhood Malignant NeoplasmPredisposition to Malignant Neoplasm

Where it's being run

7 sites across 7 states
Georgia1
Massachusetts1
Pennsylvania1
Tennessee1
Texas1
Utah1
Ontario1

Study leadership

  • Christopher Porter, MD · PRINCIPAL_INVESTIGATOR · Emory University
  • Anita Villani, MD · PRINCIPAL_INVESTIGATOR · The Hospital for Sick Children

Who to contact

Christopher Porter, MD
[email protected]
4047274881
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Based on clinical laboratory testing demonstrating a Pathogenic or Likely Pathogenic germline variant and/or
Based on well-established clinical diagnostic criteria and/or
Based on high clinical suspicion of a specific CPS with clinical laboratory testing demonstrating a variant of uncertain significance (VUS)

Exclusion

Individuals with a strong personal or family history of cancer without a genetic or clinical diagnosis of a specific CPS are not eligible for enrollment.

What this trial measures

  • Establish and maintain a framework for recruitment, participation, and surveillance of children with cancer predisposition syndromes (CPS) in clinical and translational research studies.Up to 10 years

    This multicenter registry and biorepository will be developed with the purpose of studying individuals at high risk for childhood cancer to improve care and outcomes for pediatric patients with cancer and those with cancer predisposition syndromes (CPS).

  • Define the natural history of disease in children with CPS.Up to 10 years

    To define the natural history of disease in children with CPS.

  • Evaluate the clinical impact and effectiveness of standard and emerging tumor surveillance strategies.Up to 10 years

    Evaluate the clinical impact and effectiveness of standard and emerging tumor surveillance strategies to improve care and outcomes for pediatric patients with cancer and those with cancer predisposition syndromes (CPS).